The US Poly (lactic-co-glycolic acid) (PLGA) market has witnessed steady growth due to increasing applications in drug delivery, tissue engineering, and biodegradable medical devices. With significant advancements in controlled drug release and emphasis on sustainable materials, the market is anticipated to grow robustly through 2035.
The economic impact of tariffs on "US PLGA Market".
Market Growth Drivers
Rising Adoption in Drug Delivery Systems: The growing need for advanced drug delivery mechanisms has accelerated demand for PLGA owing to its biocompatibility and biodegradability. Companies like Evonik Industries AG are expanding their PLGA-based drug delivery solutions, providing customizable release profiles for complex pharmaceuticals, thus improving patient outcomes and compliance.
Expanding Applications in Tissue Engineering: Increased research in regenerative medicine and tissue engineering has amplified PLGA utilization as a scaffolding material. Corbion N.V., for example, has collaborated with healthcare research institutes to provide high-purity PLGA for developing artificial tissues, helping to address issues such as organ shortages and chronic tissue injuries.
Latest Market Trends
Integration of Nanotechnology in PLGA Formulations: Market players like Ashland Inc. are investing in nano-enabled PLGA products for enhanced therapeutic efficacy. The trend of incorporating nanotechnology enables precision targeting and controlled release, catering to oncology and chronic disease segments.
Shift Towards Sustainable and Fully Degradable Polymers: With increasing regulatory focus on eco-friendly medical devices, PLGA’s complete biodegradability is driving its selection. Companies such as PolySciTech (Akina, Inc.) are innovating new PLGA grades with improved degradation profiles for greener healthcare solutions.
Market Opportunities
Emergence of Personalized Medicine: Tailoring PLGA-based drug delivery to individual patient profiles opens massive market potential, with companies like Evonik collaborating with pharmaceutical firms for custom solutions.
Expansion into 3D-Printed Medical Devices: Growing 3D printing adoption allows for the fabrication of PLGA-based implants and scaffolds with complex architectures, expanding opportunities for device manufacturers.
The US PLGA market revenue chart demonstrates a steady increase from $210 million in 2020 to a projected $870 million by 2035. The rapid adoption in biomedical applications and expanding research grants in the US have contributed to consistent year-over-year growth. Notably, the CAGR of approximately 10.4% from 2024 to 2035 reflects robust investment in advanced drug delivery platforms and medical-grade polymer innovation. The forecasted trajectory signals high market potential, particularly as regulatory approvals become streamlined and industry partnerships flourish.
US PLGA Market Share by Region, 2025
The regional share pie chart for the US PLGA market in 2025 highlights dominant contributions from the Northeast (34%) and Midwest (27%), reflecting concentrated pharmaceutical and biotech industries in these regions. The West (16%) and South (15%) also present significant shares driven by expansion in medical device manufacturing and university-led research. The Southwest region accounts for the remaining 8% share, indicating growing but relatively new investments in PLGA-based biomedical research and applications.
Recent Developments in the US PLGA Market (Last 6 Months)
In March 2024, Evonik Industries AG announced the launch of a next-generation RESOMER® PLGA platform with improved processability for injectable drug products. This innovation aims to address challenges in large-scale manufacturing by offering enhanced batch consistency and customizable degradation rates for emerging biologics and peptide-based therapies.
In May 2024, PolySciTech (Akina, Inc.) entered into a partnership with a leading US academic medical center to develop PLGA-based 3D printed scaffolds for bone regeneration. The joint project leverages Akina’s advanced polymer synthesis capabilities and the center’s expertise in translational research, aiming to commercialize personalized implants for orthopedic surgery.
In February 2024, Corbion N.V. reported FDA clearance for their medical-grade PURASORB® PLGA resin in a new biodegradable implantable device designed for controlled drug delivery. Collaborating with a US-based medtech firm, this milestone underscores the growing trend of regulatory approvals and market entry for innovative PLGA formulations in the US healthcare landscape.
Press Releases